For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Vyndamax and the formulated version represents a genuine advancement . These innovative therapies protect the transthyretin protein, preventing its damaging build-up and reducing the severity of the disease . Individuals are now seeing benefit